Highlight Therapeutics SL

[Highlight Therapeutics SL @Highlight_HLT]

Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
https://t.co/wBcysEPGEy

#BO112 #HighlightTherapeutics
#Immunotherapy #Intratumoral #melanoma

[Highlight Therapeutics SL @Highlight_HLT]

Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

https://t.co/6BduYggnGf

#BO112 #HighlightTherapeutics
#Immunotherapy #Intratumoral #melanoma

[Highlight Therapeutics SL @Highlight_HLT]

Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer @jitc

https://t.co/o1ukSP4R60

#BO112 #HighlightTherapeutics
#Immunotherapy #Intratumoral #SPOTLIGHT203 #melanoma

[Highlight Therapeutics SL @Highlight_HLT]

Breakthrough cancer treatment shows best-in-class potential to open up 2nd-line immunotherapy market to anti-PD1 resistant patients.

https://t.co/aF4an1S3yo

#BO112 #HighlightTherapeutics
#Immunotherapy #Intratumoral #SPOTLIGHT203 #KEYNOTEB77 #melanoma #SITC21 #sitc2021

[Highlight Therapeutics SL @Highlight_HLT]

Join the Startup Competition of #SouthSummit15! Don't miss this opportunity http://t.co/AUgjzLpZ28

[AACR @AACR]

More than 18,000 people are gathered here at #AACR14 in San Diego.

[Highlight Therapeutics SL @Highlight_HLT]

The American Association for Cancer Research annual meeting is being held these days, April 5-9 in San Diego. Follow the hashtag #AACR14

[Highlight Therapeutics SL @Highlight_HLT]

Spanish biotech company Oryzon Genomics signs licensing deal with Roche. Congrats! http://t.co/Q5tJM8Qc69

[Juan P. Serrate, DVM @JPZaragoza1]

Tomorrow morning a deal btw a Spanish biotech company & a big pharma will be announced according to @asebio Cant wait to know who they are!

[AACR @AACR]

We'll be tweeting live from the first #AACR14 press conference in about 15 minutes.

[Laura Strong @scientre]

Schlegel: PIK3Calpha inhib+RAF inhib also eff vs BRAFV600E CRC. Triple combo effectively silences both MAPK & PIK3C #AACR14

[Highlight Therapeutics SL @Highlight_HLT]

BRAF Inhibs Induce Mets in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling http://t.co/tSaR3p4uht

[Highlight Therapeutics SL @Highlight_HLT]

Deals Of The Week Looks At 2014 Takeout Targets http://t.co/0hK0jOA3SG

[CNIO Stop Cancer @CNIOStopCancer]

@CNIO_Cancer undergraduate summer programme now open for applications. Deadline 27 April http://t.co/OJxB7SHokh

[CNIO Stop Cancer @CNIOStopCancer]

CNIO-Merck alliance receives prize from @CFarmaceutico, Pharmacological Research and Products category http://t.co/H8aj587YoP

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

Do investment bankers, CFOs, and GCs make successful Business Development Executives? Join the debate @ Allicense2014 http://t.co/QJDxTJJ0MF

[John Carroll @JohnCendpts]

Will Peter Thiel's Founder Fund put some of its new $1B fund in biotech? http://t.co/lfUnbeB1XG

[Highlight Therapeutics SL @Highlight_HLT]

Immuno Oncology – A 30-year Overnight Success Story http://t.co/hW6xQsR8hl via @IAmBiotech

[Highlight Therapeutics SL @Highlight_HLT]

FivePrime and Bristol-Myers strike immuno-oncology deal http://t.co/I40nyHtuCe

[Eric D Whitman, MD @Melanoma_doctor]

Survival improvement with #Zelboraf Rx for v600k mutated #melanoma, not just v600e mutations. http://t.co/0dJSqo3Xj3